What is ADVB's market cap?

$3.70M, based on the Nov 4 close of $2.24.

What is ADVB's P/E ratio?

0.6× trailing-twelve-month earnings of $6.68M.

Does Advanced Biomed pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ADVB is sold short?

9.7K shares, 1.0% of float, as of Oct 15, 2026.

What sector is ADVB in?

Healthcare, in the Medical Labs industry.

NASDAQ · ADVBHealthcareMedical Labs

Advanced Biomed Inc. Common Stock (ADVB)

$2.24+1.82%

Close Nov 4, 2026 · split-adjusted

Oct 30, 2026$2.30▼ 75.02% in range

Nov 3, 2025Low $2.30 · High $18.98Oct 30, 2026

What changed · written from our data

As of Nov 4, 2026

Advanced Biomed closed at $2.24 on Nov 4, up 1.82%, 88.2% below its 52-week closing high. Volume of 18.3K shares was 0.48× its 20-day average (below normal).

Split-adjusted performance: -64.9% over one month, -67.0% over six months, -75.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $127.64K, with a net margin of 544.5%.

Short interest was 9.7K shares at the Oct 15 settlement, down 48.4% from the prior report (1.0% of float, 1.0 days to cover).

Market cap$3.7M1.7M shares

Revenue · quarter$127.6K—

Diluted EPS$0.44—

P/E · TTM0.6×P/S 29.0×

Net margin544.5%Gross 100.0%

Dividend yieldNone

52-week range2.08 – 18.98−88.2% from high

Volume18.3K0.48× 20-day avg

Volatility · 60d106.4%Annualised

Short % of float1.0%1.0 days to cover

Net cash$385.5KCash $385.5K

Next earnings—Not scheduled

Split-adjusted performance

1W −24.8%1M −64.9%3M −69.9%6M −67.0%YTD −61.6%1Y −75.7%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum0

Revenue growth—

Net margin100

Value (low P/E)—

Size4

Industry medians: 6-month return +36.5%, revenue growth +25.0%, net margin −4.0%, P/E 32.5×.

Short interest

Details →

Shares short9.7K−48.4% vs prior

Days to cover1.0Settled Oct 15

% of float1.0%

Short vol. 10d45.1%of daily volume

Closest peers by size in Medical Labs

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ADVBAdvanced Biomed	$2.24	+1.82%	−67.0%	—	544.5%	0.6	$3.7M
BGLCBioNexus Gene Lab	$0.9400	−1.05%	−53.0%	−96.6%	−376.1%	—	$2.8M	Compare
ACONAclarion	$1.77	+0.68%	−46.0%	+30.5%	−10899.5%	—	$5.1M	Compare
AMSAmerican Shared Hospital Services	$1.24	+0.81%	−31.5%	+19.2%	−6.1%	—	$8.2M	Compare
SERASera Prognostics	$2.06	+6.61%	+13.7%	+76.5%	−30463.3%	—	$81.2M	Compare
XGNExagen	$8.53	+2.30%	+176.1%	+15.9%	−16.0%	—	$206.7M	Compare
BDSXBiodesix	$21.44	+1.85%	+42.9%	+34.2%	−27.1%	—	$226.2M	Compare
FLGTFulgent Genetics	$19.86	+2.50%	+33.1%	+4.4%	−34.6%	—	$546.3M	Compare
CSTLCastle Biosciences	$35.94	+2.28%	+45.2%	+20.1%	−2.0%	—	$1.10B	Compare

News about Advanced Biomed

All news →

No recent articles focused on Advanced Biomed.

Quick answers

What does Advanced Biomed do?: Advanced Biomed Inc operates through its subsidiary as an AI financial verification company focused on financial verification and other professional, regulated use cases. The Group develops and operates the FinTruth Financial Verification Agent Platform (FinTruth), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results.
What is ADVB's market cap?: $3.70M, based on the Nov 4 close of $2.24.
What is ADVB's P/E ratio?: 0.6× trailing-twelve-month earnings of $6.68M.
Does Advanced Biomed pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ADVB is sold short?: 9.7K shares, 1.0% of float, as of Oct 15, 2026.
What sector is ADVB in?: Healthcare, in the Medical Labs industry.

About Advanced Biomed

Advanced Biomed Inc operates through its subsidiary as an AI financial verification company focused on financial verification and other professional, regulated use cases. The Group develops and operates the FinTruth Financial Verification Agent Platform (FinTruth), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. It focuses on establishing recurring and usage-based enterprise revenue from its AI technology operations. The Group has one reportable segment, consisting mainly of its technology and software-related operations.

HQ: Reno, NV12 employeesListed Mar 6, 2025advb.ai

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology